Brief: AB Science: New Publication Says Masitinib Has Anti-Vital Activity Against SARS-CoV-2 Virus

AB Science SA

25/01/2021 07:39

Jan 25 (Reuters) - AB SCIENCE SA  ABS.PA :
    * ANNOUNCES THAT A NEW INDEPENDENT PUBLICATION CONFIRMS THAT
MASITINIB HAS ANTI-VITAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS
IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19
    * HAS BEEN GRANTED AUTHORIZATION BY FRENCH MEDICINE AGENCY
(ANSM)
TO INITIATE A CLINICAL STUDY EVALUATING MASITINIB IN COMBINATION
WITH ISOQUERCETIN FOR TREATMENT OF COVID-19
    * THIS STUDY (AB20001) IS A RANDOMIZED (1:1), OPEN-LABEL
PHASE 2
CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF MASITINIB
COMBINED WITH ISOQUERCETIN IN HOSPITALIZED PATIENTS WITH
MODERATE AND SEVERE COVID-19
    * STUDY WILL ENROLL 200 PATIENTS (AGE ≥18 WITHOUT AN UPPER
AGE
LIMIT) AT MEDICAL CENTERS IN FRANCE AND OTHER COUNTRIES.
    * PRIMARY OBJECTIVE IS TO IMPROVE CLINICAL STATUS OF
PATIENTS
AFTER 15 DAYS OF TREATMENT.
    * PRIMARY OBJECTIVE IS TO IMPROVE CLINICAL STATUS OF
PATIENTS
AFTER 15 DAYS OF TREATMENT

Source text for Eikon:  ID:nGNEch6hCt 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))